Neoplasm

Microarray-based comparative genomic hybridization (aCGH) analysis was carried out on 58 Wilms’ tumor samples. 38 tumors were untreated primary and 20 were recurrent. An increase in copy number change… (full text at CIViC)

PMID 17103382 · Natrajan et al., 2007 · Open in CIViC

77 tumors from Wilms Tumor patients were tested with Illumina BeadChip arrays and genomic profiles were tested for association with relapse and other clinicopathological variables. Copy number gain at… (full text at CIViC)

PMID 22407497 · Perotti et al., 2012 · Open in CIViC

Anaplastic histology (AH) in Wilm's Tumor is characterized by abnormal mitoses, and associated with poor prognosis in comparison to favorable histology (FH). Array CGH was used on 53 AH samples, and a… (full text at CIViC)

PMID 21882282 · Williams et al., 2011 · Open in CIViC

A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. ABCB1 C3435T carriers had a longer progression-free survival (p = 0.039) along… (full text at CIViC)

PMID 22906996 · Kim et al., 2012 · Open in CIViC

The mutation at codon 3435 (C>T) correlated with a significantly higher response rate to platinum-based chemotherapy in patients with advanced non small cell lung cancer (NSCLC). 103 Chinese patients… (full text at CIViC)

PMID 22296372 · Yan et al., 2011 · Open in CIViC

The BCR-ABL1 expressing imatinib-resistant cell line K562/D1-9 overexpresses P-glycoprotein (ABCB1), a known drug membrane transporter. Bafetinib (INNO-406) and dasatinib showed drastically higher IC5… (full text at CIViC)

PMID 18191450 · Deguchi et al., 2008 · Open in CIViC

mRNA expression of ABCB1 in 17 NSCLC cell lines was associated with decreased response to paclitaxel (correlation of mRNA expression and paclitaxel IC50: r=0.5322, P=0.0279).

PMID 21883677 · Meng et al., 2011 · Open in CIViC

A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. ABCB1 G2677T carriers had a longer progression-free survival (p = 0.037) along… (full text at CIViC)

PMID 22906996 · Kim et al., 2012 · Open in CIViC

The ABCB1 G2677T/A (S893T, rs2032582) homozygous variant was positively correlated with response to paclitaxel treatment in ovarian cancer patients. 51 epithelial and 2 fallopian tube frozen tumors we… (full text at CIViC)

PMID 16467099 · Gréen et al., 2006 · Open in CIViC

Increased expression of ABCC10 in 17 NSCLC cell lines was inversely correlated with paclitaxel sensitivity (r = 0.574; P < 0.05).

PMID 18445659 · Oguri et al., 2008 · Open in CIViC

44 cell lines and 145 patient samples were utilized in various aspects of this study. 31 breast cancer cell lines for in vitro sensitivity to paclitaxel and Monomethyl Auristatin E (MMAE). Genome wide… (full text at CIViC)

PMID 18593940 · O'Brien et al., 2008 · Open in CIViC

The ABCG2 Q141K variant was correlated with higher progression-free survival and overall survival in 511 ovarian cancer patients treated with platinum + taxane-based chemotherapy.

PMID 22112610 · Tian et al., 2012 · Open in CIViC

In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations … (full text at CIViC)

PMID 15930265 · O'Hare et al., 2005 · Open in CIViC

One chronic myeloid leukemia patient in chronic phase had a minimal best cytogenetic response to imatinib but became resistant. Bacterial clones generated using peripheral blood RNA later showed the B… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The E255V mutation in th… (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

In a retrospective study (of phase 3 clinical trial NCT00481247) of 363 Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia patients in chronic phase, a patient with the F317I mutation in … (full text at CIViC)

PMID 26118315 · Hughes et al., 2015 · Open in CIViC

In a study of 51 imatinib-resistant chronic myeloid leukemia patients, patients with the F317L or F317V mutation in the ABL1 portion of the BCR-ABL1 gene fusion (n=10) were associated with acquired re… (full text at CIViC)

PMID 27485109 · Soverini et al., 2016 · Open in CIViC

In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The F359C mutation in th… (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

In an in vitro study which involved the use of a line of wild-type Ikaros-inducible IKZF1 mutant human precursor B cells (a model of BCR-ABL1+ precursor B cell acute lymphoblastic leukemia [pre-B ALL]… (full text at CIViC)

PMID 28190001 · Schjerven et al., 2017 · Open in CIViC

In a retrospective study of 84 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1 fusion positive (Ph+) chronic myeloid leukemia (in accelerated-phase or with blast crisis) or Ph+ acut… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L248V mutation in th… (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations … (full text at CIViC)

PMID 15930265 · O'Hare et al., 2005 · Open in CIViC

In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations … (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in accelerated phase had the BCR-ABL1 fusion with G250E/E138G/I242T/K271R/V338M, G250E/E138G/I242T/K271R, G25… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

One chronic myeloid leukemia patient in chronic phase with the BCR-ABL1 fusion and the V186A secondary variant in 2/12 clones had no response to imatinib before becoming completely resistant.

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

One chronic myeloid leukemia patient in chronic phase with the BCR-ABL1 fusion and the Y253H secondary variant in 11/11 clones had complete cytogenetic best cytogenetic response to imatinib before bec… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The Y253H mutation in th… (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

In a study of 39 chronic phase CML patients with BCR-ABL variants, C475V was seen in a single imatinib resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. … (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A chronic-phase patient had a partial hematologi… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 2 had E255K mutations

PMID 17264298 · Guilhot et al., 2007 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In a retrospective study of 174 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1fusion positive accelerated phase chronic myeloid leukemia patients, patients with mutations in the AB… (full text at CIViC)

PMID 19487385 · Apperley et al., 2009 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

In a study of 51 imatinib-resistant chronic myeloid leukemia patients, patients with the F317L or F317V mutation in the ABL1 portion of the BCR-ABL1 gene fusion (n=10) were associated with acquired re… (full text at CIViC)

PMID 27485109 · Soverini et al., 2016 · Open in CIViC

In a retrospective study of 118 imatinib-resistant or -intolerant, Philadelphia chromosome BCR-ABL1 fusion positive, chronic myeloid leukemia (chronic phase) patients, no response to dasatinib monothe… (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

In an in vitro study, a Ba/F3 murine cell line stably expressing the F486S mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to bosutinib treatment (I… (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC